Premium
Speeding tumor genotyping during the SARS‐CoV‐2 outbreak through liquid biopsy
Author(s) -
Rolfo Christian,
Russo Alessandro,
MiguelPérez Diego
Publication year - 2020
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.32983
Subject(s) - medicine , liquid biopsy , genotyping , outbreak , covid-19 , intensive care medicine , biopsy , turnaround time , cancer , pathology , disease , genotype , gene , infectious disease (medical specialty) , biochemistry , chemistry , computer science , operating system
This commentary proposes a shift in the current diagnostic workflow for patients with metastatic cancer to incorporate the use of liquid biopsy. This proposal, born in the time of a severe crisis for the health care system, might also be applied when the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) outbreak ends and thereby reduce the turnaround time for results from molecular testing for patients with cancer and increase the number of patients potentially benefiting from highly effective targeted therapies.